Protalix BioTherapeutics, Inc. Common Stock (PLX) is a publicly traded Healthcare sector company. As of May 21, 2026, PLX trades at $1.94 with a market cap of $153.89M and a P/E ratio of 10.07. PLX moved +5.53% today. Year to date, PLX is +12.29%; over the trailing twelve months it is +16.86%. Its 52-week range spans $0.99 to $3.19. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces PLX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for PLX combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $1.94 |
| Market Cap | $153.89M |
| P/E Ratio | 10.07 |
| EPS | $0.20 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.19 |
| 52-Week Low | $0.99 |
| Volume | 30 |
| Avg Volume | 0 |
| Revenue (TTM) | $76.38M |
| Net Income | $15.33M |
| Gross Margin | 69.97% |
1 analysts cover PLX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.